Regen BioPharma, Inc. (OTCMKTS:RGBP) Short Interest Down 20.8% in September

by · The Markets Daily

Regen BioPharma, Inc. (OTCMKTS:RGBP – Get Free Report) was the target of a significant decrease in short interest during the month of September. As of September 15th, there was short interest totalling 1,900 shares, a decrease of 20.8% from the August 31st total of 2,400 shares. Based on an average daily volume of 6,000 shares, the days-to-cover ratio is presently 0.3 days.

Regen BioPharma Stock Performance

The stock’s fifty day moving average is 0.30 and its two-hundred day moving average is 0.32. Regen BioPharma has a 12 month low of 0.12 and a 12 month high of 1.96.

About Regen BioPharma

(Get Free Report)

Regen BioPharma, Inc focuses on the development of regenerative medical applications in the United States. It engages in identifying small molecules that inhibit or express NR2F6 leading to immune cell activation for oncology applications, and immune cell suppression for autoimmune disease. The company is involved in the development of its products, and therapies, including HemaXellarate, a cellular therapeutic product of autologous stromal vascular fraction derived from adipose tissue; dCellVax, an autologous dendritic cell which is treated with an siRNA inhibitor of indoleamine-2,3-dioxygenase; tCellVax which is treated with siRNA to inhibit NR2F6 and the cells re-infused to the patient; DiffronC, uses proprietary siRNA in vivo to inhibit cancer growth and activate T cells; and DuroCAR comprising of CAR-T cells which is treated with an shRNA targeting the gene NR2F6.

Featured Articles